Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...
Amid backlash, FDA changes course over shortage of weight-loss drugs
The FDA said Eli Lilly’s weight-loss drugs were no longer in shortage on Oct. 2, preventing pharmacies from making cheaper ...
FDA says this weight loss drug shortage is over, but patients worry about cost and availability
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
Monthly Prescribing Reference4h
FDA Issues Safety Alert for Compounded Drugs Distributed by CA Facility
The FDA is urging patients who have received drugs from Fullerton Wellness to stop using them and contact their health care provider.
Health on MSN19d
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss Drugs
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
BioSpace4d
FDA Says All Doses of Novo’s Ozempic, Wegovy Now Available
Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up ...
STAT10d
Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight
A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...
FDA's Weight Loss Drug 'No Man's Land' Adds Risk for Compounders
Pharmacies currently making copycat versions of Eli Lilly’s tirzepatide face heightened exposure to state enforcement actions ...
Ozempic, Wegovy move closer to no longer being in shortage, FDA says
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...
JD Supra28d
GLP-1 Drugs: FDA Removes Lilly’s Zepbound® and Mounjaro® (tirzepatide injection) from its Drug Shortage List
On October 2, 2024, the U.S. Food and Drug Administration (FDA) determined the shortage of the tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been “resolved”.